U.S. markets open in 8 hours 34 minutes
  • S&P Futures

    +29.00 (+0.76%)
  • Dow Futures

    +195.00 (+0.61%)
  • Nasdaq Futures

    +144.50 (+1.18%)
  • Russell 2000 Futures

    +16.50 (+0.75%)
  • Crude Oil

    +0.34 (+0.52%)
  • Gold

    +8.30 (+0.49%)
  • Silver

    +0.13 (+0.52%)

    +0.0008 (+0.07%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.81 (+3.28%)

    +0.0019 (+0.13%)

    +0.2690 (+0.25%)

    +3,678.78 (+7.30%)
  • CMC Crypto 200

    +66.84 (+6.53%)
  • FTSE 100

    +88.61 (+1.34%)
  • Nikkei 225

    +236.80 (+0.82%)

Worldwide Industry for Insulin Delivery Systems to 2025 - Featuring Sanofi, Tandem Diabetes Care and Ypsomed Holding Among Others

·8 min read

DUBLIN, Jan. 22, 2021 /PRNewswire/ -- The "Insulin Delivery System Market Research Report by Product Type (Insulin Jet Injectors, Insulin Pens, Insulin Pumps, and Syringes), by End User (Hospitals, Retail channels, and Specialty Diabetic Clinics) - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Insulin Delivery System Market including Animas Corporation (Johnson and Johnson), Becton, Dickinson and Company, Biocon Limited, Eli Lilly and Company, Insulet Corporation, Medtronic PLC, Novo Nordisk A/S, Sanofi, Tandem Diabetes Care, Inc., and Ypsomed Holding AG.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Insulin Delivery System Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Insulin Delivery System Market is expected to grow from USD 13,389.33 Million in 2020 to USD 18,646.20 Million by the end of 2025.

2. The Global Insulin Delivery System Market is expected to grow from EUR 11,740.02 Million in 2020 to EUR 16,349.34 Million by the end of 2025.

3. The Global Insulin Delivery System Market is expected to grow from GBP 10,436.90 Million in 2020 to GBP 14,534.60 Million by the end of 2025.

4. The Global Insulin Delivery System Market is expected to grow from JPY 1,428,981.23 Million in 2020 to JPY 1,990,022.54 Million by the end of 2025.

5. The Global Insulin Delivery System Market is expected to grow from AUD 19,443.09 Million in 2020 to AUD 27,076.76 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Insulin Delivery System to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Product Type, the Insulin Delivery System Market is examined across Insulin Jet Injectors, Insulin Pens, Insulin Pumps, and Syringes.

  • Based on End User, the Insulin Delivery System Market is examined across Hospitals, Retail channels, and Specialty Diabetic Clinics.

  • Based on Geography, the Insulin Delivery System Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Insulin Delivery System Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Insulin Delivery System Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Insulin Delivery System Market?
4. What is the competitive strategic window for opportunities in the Global Insulin Delivery System Market?
5. What are the technology trends and regulatory frameworks in the Global Insulin Delivery System Market?
6. What are the modes and strategic moves considered suitable for entering the Global Insulin Delivery System Market?

Key Topics Covered:

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Product Type Outlook
3.4. End User Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
4.3. Geographic Growth Opportunities

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Global Insulin Delivery System Market, By Product Type
6.1. Introduction
6.2. Insulin Jet Injectors
6.3. Insulin Pens
6.4. Insulin Pumps
6.5. Syringes

7. Global Insulin Delivery System Market, By End User
7.1. Introduction
7.2. Hospitals
7.3. Retail channels
7.4. Specialty Diabetic Clinics

8. Americas Insulin Delivery System Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Insulin Delivery System Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand

10. Europe, Middle East & Africa Insulin Delivery System Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Animas Corporation (Johnson and Johnson)
12.2. Becton, Dickinson and Company
12.3. Biocon Limited
12.4. Eli Lilly and Company
12.5. Insulet Corporation
12.6. Medtronic PLC
12.7. Novo Nordisk A/S
12.8. Sanofi
12.9. Tandem Diabetes Care, Inc.
12.10. Ypsomed Holding AG

13. Appendix
13.1. Discussion Guide

For more information about this report visit https://www.researchandmarkets.com/r/cpefss

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:http://www.prnewswire.com/news-releases/worldwide-industry-for-insulin-delivery-systems-to-2025---featuring-sanofi-tandem-diabetes-care-and-ypsomed-holding-among-others-301213197.html

SOURCE Research and Markets